Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PRPH – ProPhase Labs Inc

ProPhase Labs, Inc.
PRPH
$0.3288
Name : ProPhase Labs, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $13,658,746.00
EPSttm : -2.07
finviz dynamic chart for PRPH
ProPhase Labs, Inc.
$0.3288
1.88%
$0.0063

Float Short %

0.37

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

-0.01

EPS Last/This Y

2.05

EPS This/Next Y

Price

0.33

Target Price

16

Analyst Recom

1

Performance Q

7.1

Relative Volume

0.1

Beta

-0.78

Ticker: PRPH




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PRPH0.45990.010.005795
2025-07-28PRPH0.450.010.027578
2025-07-29PRPH0.35130.010.047753
2025-07-30PRPH0.35130.010.007851
2025-07-31PRPH0.35780.010.088059
2025-08-01PRPH0.32610.010.008180
2025-08-04PRPH0.31250.010.008372
2025-08-05PRPH0.31380.010.008484
2025-08-06PRPH0.31240.010.008494
2025-08-07PRPH0.32220.010.008583
2025-08-08PRPH0.31710.010.008795
2025-08-11PRPH0.27820.010.008949
2025-08-12PRPH0.3520.010.039246
2025-08-13PRPH0.3250.010.0111113
2025-08-14PRPH0.33860.010.0011608
2025-08-15PRPH0.34020.010.1011830
2025-08-18PRPH0.340.010.0010636
2025-08-19PRPH0.31260.010.0010908
2025-08-20PRPH0.32980.010.0010947
2025-08-21PRPH0.33980.010.0111122
2025-08-22PRPH0.33160.010.0011331
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PRPH0.4754.6- -0.56
2025-07-28PRPH0.4554.6- -0.56
2025-07-29PRPH0.3554.6- -0.56
2025-07-30PRPH0.3654.6- -0.56
2025-07-31PRPH0.3654.6- -0.56
2025-08-01PRPH0.3354.6- -0.56
2025-08-04PRPH0.3154.6- -0.56
2025-08-05PRPH0.3154.6- -0.56
2025-08-06PRPH0.3154.6- -0.56
2025-08-07PRPH0.3354.6- -0.56
2025-08-08PRPH0.3154.6- -0.56
2025-08-11PRPH0.2854.6- -0.56
2025-08-12PRPH0.3554.6- -0.56
2025-08-13PRPH0.3354.6- -0.56
2025-08-14PRPH0.3354.6- -0.56
2025-08-15PRPH0.3454.6- -0.56
2025-08-18PRPH0.3454.6- -0.56
2025-08-19PRPH0.3154.6- -0.56
2025-08-20PRPH0.3354.6- -0.56
2025-08-21PRPH0.3354.6- -0.56
2025-08-22PRPH0.3368.6- -0.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PRPH0.0092.200.39
2025-07-28PRPH0.0091.230.39
2025-07-29PRPH0.0091.230.39
2025-07-30PRPH0.0091.230.39
2025-07-31PRPH0.0091.230.39
2025-08-01PRPH0.0091.230.39
2025-08-04PRPH0.0088.780.39
2025-08-05PRPH0.0088.780.39
2025-08-06PRPH0.0088.780.39
2025-08-07PRPH0.0088.780.39
2025-08-08PRPH0.0088.780.39
2025-08-11PRPH0.0095.110.39
2025-08-12PRPH0.0095.110.37
2025-08-13PRPH0.0095.110.37
2025-08-14PRPH0.0095.110.37
2025-08-15PRPH0.0095.110.37
2025-08-18PRPH0.0081.730.37
2025-08-19PRPH0.0081.730.37
2025-08-20PRPH0.0081.730.37
2025-08-21PRPH0.0081.730.37
2025-08-22PRPH0.0081.730.37
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

81.73

Beta

-0.78

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

23

Growth Score

29

Sentiment Score

82

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-98.4

Target Price

16

P/E

Forward P/E

PEG

P/S

1.07

P/B

1.19

P/Free Cash Flow

EPS

-1.5

Average EPS Est. Cur. Y​

-0.56

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-217.64

Relative Volume

0.1

Return on Equity vs Sector %

-387.2

Return on Equity vs Industry %

-373.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.24

EBIT Estimation

ProPhase Labs, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 96
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today
news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance
stock history PRPH – ProPhase Labs Inc invest stock market
stock prices PRPH premarket after hours
ticker PRPH fair value insiders trading